Prediction of survival and therapy outcome with 11C-tyrosine PET in patients with laryngeal carcinoma

J Nucl Med. 2004 Dec;45(12):2052-7.

Abstract

Choosing the optimal treatment for an individual with squamous cell carcinoma of the head and neck is a difficult challenge because of the unpredictable clinical behavior of this malignancy. A reliable method for assessing the clinical behavior and predicting the radiocurability of tumors would assist in the therapy strategy and prognosis. This study evaluated whether quantitative PET using l-[1-(11)C]-tyrosine (TYR) has predictive value for survival and therapy outcome in patients with primary squamous cell carcinoma of the larynx.

Methods: Thirty-four patients with histologically confirmed laryngeal carcinomas underwent dynamic (11)C-TYR PET before receiving definitive therapy. Various methods for quantification of tumor activity were used: assessment of protein synthesis rate (PSR), calculation of standardized uptake value, and estimation of tumor-to-nontumor ratio. Treatment consisted of radiotherapy (n = 20) or surgery (n = 14). The median follow-up was 40 mo.

Results: All malignancies were identified correctly, with no false-negative results. Cumulative survival was compared between patients with tumor PSR equal to or higher than the median (2.0 nmol/mL/min) and those with tumor PSR lower than the median and was found not to be significantly different (P = 0.07). When the radiotherapy group was evaluated separately, the difference in survival was significant (P = 0.03; 5-y survival, 30% vs. 73%) and high (11)C-TYR uptake correlated with poor prognosis. In multivariate analysis, PSR was an independent predictor for survival. Because differences (P = 0.08) between patients with and patients without recurrence were not significant, no predictive value of PSR for disease recurrence could be demonstrated.

Conclusion: Prediction of survival of patients undergoing radiotherapy for laryngeal squamous cell carcinoma is feasible primarily by using (11)C-TYR PET to quantify activity before treatment.

MeSH terms

  • Adult
  • Aged
  • Carbon Radioisotopes*
  • Carcinoma, Squamous Cell / diagnostic imaging*
  • Carcinoma, Squamous Cell / metabolism
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / radiotherapy
  • Female
  • Humans
  • Laryngeal Neoplasms / diagnostic imaging*
  • Laryngeal Neoplasms / metabolism
  • Laryngeal Neoplasms / mortality
  • Laryngeal Neoplasms / radiotherapy
  • Male
  • Middle Aged
  • Positron-Emission Tomography / methods*
  • Survival Rate
  • Tyrosine*

Substances

  • Carbon Radioisotopes
  • Tyrosine